Biologic rheumatoid arthritis therapies: Do we need more comparative effectiveness data?

BioDrugs

Volumn 26, Issue 2, 2012, Pages 65-70

  Levesque, Marc C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biological products; Disease modifying antirheumatics; Rheumatoid arthritis.

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; COMPARATIVE EFFECTIVENESS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS (TOPIC); OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857831726     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11631320-000000000-00000     Document Type: Review

References (33)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58 (1): 15-25
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358 (9285): 903-11
3. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370 (9602): 1861-74
4. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001; 44 (12): 2746-9
5. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: Health burden and costs. Eur J Health Econ 2008; 8 Suppl. 2: S49-60
6. Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): Descriptive analysis from the first 20,000 subjects. Value Health 2005; 8 (5): 581-90
7. Allaire S, Wolfe F, Niu J, et al. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 2008; 59 (4): 474-80
8. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: An update. Expert Opin Pharmacother 2007; 8 (13): 2089-107
9. IOM. Institute of Medicine (IOM) report on national priorities for clinical research, 2009 [online]. Available from URL: www.nap.edu/catalog/12648. html [Accessed 2012 Feb 14]
10. Sox HC, Greenfield S. Comparative effectiveness research: A report from the Institute of Medicine. Ann Intern Med 2009; 151 (3): 203-5
11. Sox HC. Comparative effectiveness research: A progress report. Ann Intern Med 2010; 153 (7): 469-72
12. O'Dell JR, Mikuls TR, Colbert RA, et al. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum 2011; 63 (8): 2151-6
13. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology 2004; 43 (1): 4-6
14. Van den Hout WB. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA. Nat Clin Pract Rheumatol 2009; 5: 78-9
15. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med Decis Making 2005; 25 (5): 520-33
16. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148 (2): 124-34
17. Siegel J. Comparative effectiveness of treatments for rheumatoid arthritis. Ann Intern Med 2008; 148 (2): 162-3
18. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 2006; 33 (12): 2398-408
19. Clark W, Jobanputra P, Barton P, et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: A systematic review and economic analysis. Health Technol Assess 2004; 8 (18): Iii-iv, ix-x, 1-105
20. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54 (2): 600-6
21. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61 (9): 793-8
22. Weaver AL, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: Results from the RADIUS observational registry. Curr Med Res Opin 2006; 22 (1): 185-98
23. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl. 2: Ii13-6
24. Venkateshan SP, Sidhu S, Malhotra S, et al. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology 2009; 83 (1): 1-9
25. Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010; 39 (6): 425-41
26. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: An indirect comparisons approach. Pharmacotherapy 2011; 31 (1): 39-51
27. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: A meta-analysis. Ann Rheum Dis 2011; 70 (2): 266-71
28. Gallego-Galisteo M, Villa-Rubio A, Alegre-Del Rey E, et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther 2011; 2011 (10): 1365-2710
29. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374: 459-66
30. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum. In press
31. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56 (5): 1417-23
32. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review. Arthritis Res Ther 2009; 11 Suppl. 1: S1
33. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double- blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67 (8): 1096-103